Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in patients with Advanced Ovarian Cancer: A 2-year survival analysis study

Abstract

During the last few years, Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has entered the national comprehensive cancer network guidelines as a new protocol for improving patients’ outcomes. However, there is no consensus on its long-term efficiency, and it still is under debate. This study aims to evaluate the effectiveness of Cytoreductive Surgery Plus hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer in Iran. Thirty patients with Stage IIIc and IV advanced ovarian cancer underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at Jam Hospital with a fixed surgical team in Tehran, Iran, from 2019 to 2021. Fourteen patients were new cases, and sixteen of them were recurrent cases. At the end of cytoreductive surgery, by using a hyperthermic intraperitoneal chemotherapy device, Cisplatin was circulated in the peritoneal cavity for 90 minutes at a dose of 80-100 mg/ m2 at 43 ° C. Among 30 patients with 54.97±10.74 years of mean age, the mean overall survival was 564.967 days, and 2-year survival rates were 66.7%. According to Fisher's exact test, there was a statistically significant relationship between disease-free after surgery and mortality rate (p=0.00). However, there was no statistically significant relationship between recurrence after surgery and mortality rate (p=0.093). Based on these findings, cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy had a survival rate of 66.7% within two years in advanced ovarian cancer patients. However, to achieve better results, careful selection of patients and complete cytoreductive surgery should be performed.